Market Cap | 27.46M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -2.83M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -3.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -66.00% |
Dividend | N/A | Price/Book | 3.28 | EPS next 5Y | - | 52W High Chg | -98.00% |
Recommedations | - | Quick Ratio | 9.40 | Shares Outstanding | 13.53M | 52W Low Chg | 50.00% |
Insider Own | 61.21% | ROA | - | Shares Float | 6.35M | Beta | - |
Inst Own | 3.69% | ROE | - | Shares Shorted/Prior | 372.11K/162.10K | Price | 2.03 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,585,255 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 147,863 | Change | -0.98% |
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Dritschilo Anatoly | CEO and Chairman CEO and Chairman | Dec 29 | Sell | 1.605 | 8,372 | 13,437 | 1,085,200 | 01/03/23 |
Rich Tyvin | Chief Medical Office.. Chief Medical Officer | Dec 29 | Sell | 1.605 | 1,414 | 2,269 | 2,429 | 01/03/23 |
Jung Mira | Chief Scientific Off.. Chief Scientific Officer | Dec 29 | Sell | 1.605 | 328 | 526 | 1,071,388 | 01/03/23 |
Jacobs Bette | Director Director | Dec 29 | Sell | 1.605 | 4,366 | 7,007 | 31,221 | 01/03/23 |
Dritschilo Peter | President and COO President and COO | Dec 29 | Sell | 1.605 | 3,820 | 6,131 | 6,560 | 12/30/22 |